Table 2.

Use of photodynamic therapy in the normal situation per country

	What is the primary treatment in your country in the normal situation?
	What percentage of patients do you estimate is treated with PDT in your country in the normal situation?
	Chronic CSC		PCV		Choroidal haemangioma		Neovascular AMD
Country	Primary treatment	% treated with PDT	Primary treatment	% treated with PDT	Primary treatment	% treated with PDT	Primary treatment	% treated with PDT
Denmark	PDT	100%	Anti‐VEGF or Anti‐VEGF + PDT	30%	PDT	100%	Anti‐VEGF	<1%
France	PDT	75%	Anti‐VEGF	5%	PDT	80%	Anti‐VEGF	1%
Germany	PDT	80%	Anti‐VEGF	5%	PDT	90%	Anti‐VEGF	<5%
Israel	PDT	90%	Anti‐VEGF or Anti‐VEGF + PDT	5–10%	PDT	90–100%	Anti‐VEGF	0%
Italy	PDT	50%	Anti‐VEGF + PDT	20%	PDT	80%	Anti‐VEGF	1%
The Netherlands	PDT	90%	Anti‐VEGF + PDT	50%	PDT	95%	Anti‐VEGF	1%
Sweden	PDT	75–100%	Anti‐VEGF	20–30%	PDT	80%	Anti‐VEGF	0%
Switzerland	PDT	100%	Anti‐VEGF or Anti‐VEGF + PDT	35–40%	PDT	100%	Anti‐VEGF	2%
United Kingdom	PDT	80%	Anti‐VEGF + PDT	50%	PDT	70%	Anti‐VEGF	5%
United States	MR antagonist (1st) or PDT (2nd)	25–50%	Anti‐VEGF or PDT	5–20%	PDT	50–80%	Anti‐VEGF	0–10%
Japan	PDT or conventional laser treatment	20%	Anti‐VEGF or Anti‐VEGF + PDT	5%	Conventional laser treatment or PDT	15%	Anti‐VEGF or Anti‐VEGF + PDT	2%
Singapore	PDT or conventional laser treatment	90%	Anti‐VEGF or Anti‐VEGF + PDT	30%	PDT	70%	Anti‐VEGF	<5%

AMD = age‐related macular degeneration; anti‐VEGF = anti‐vascular endothelial growth factor; CSC = central serous chorioretinopathy; MR = mineralocorticoid receptor; PCV = polypoidal choroidal vasculopathy; PDT = photodynamic therapy.